Charles River Laboratories International Inc. (NYSE: CRL), fresh from the collapse of a proposed, $1.6 billion merger with WuXi PharmaTech (Cayman) Inc. (NYSE: WX), plans to accelerate a $300 million stock buyback and took out a $750 million credit line.
The Wilmington, Massachusetts-based contract research organization said the repurchasing plan will see it buy back 6 million shares initially, with the final number to be determined based on a discounted price based on its daily volume-weighted average price during a a six-month-or-less period as determined by Morgan Stanley & Co. Inc., which is brokering the buyback.
Charles River Labs said it will pay for the buyback using cash on hand and “available liquidity,” which includes a new $750 million credit agreement. The new line consists of a $400 million term loan and a $350 million revolving credit facility.
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
The company spiked the WuXi merger in late July after running into a buzz saw of opposition from several institutional backers, who believed the deal was too pricey and would give WuXi a disproportionately large stake in the combined companies.
The failed merger only added to Charles River Labs’ woes during the second quarter, when it posted a 57.6 percent decline in profits on a 5.2 percent top-line slide and cut its sales and earnings forecast for the rest of the year.
CRL shares were trading at $29.06 in early-morning activity, up about 0.6 percent.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.